FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Amicus Therapeutics, Inc.

1 Cedar Brook Drive
Cranbury, NJ 08512
United States

Full Time Employees508

Key Executives

NameTitlePayExercisedYear Born
Mr. John F. CrowleyChairman & CEO1.9MN/A1967
Mr. Bradley L. Campbell M.B.A.Pres, COO & Director812.03k185.55k1976
Ms. Ellen S. RosenbergChief Legal Officer & Corp. Sec.653.34kN/A1963
Dr. Jay A. BarthChief Medical Officer668.71k537.04k1964
Ms. Daphne E. QuimiChief Financial OfficerN/AN/A1966
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 1/2 (ATB200-02) and Phase 3 (ATB200-03) clinical studies for Pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies; and a strategic manufacturing agreement with Catalent Biologics. The company also has a strategic manufacturing collaboration with Thermo Fisher Scientific for conducting preclinical and clinical-stage gene therapy programs for CLN6, CLN3, and other Batten disease programs. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Corporate Governance

Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.